Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Evacetrapib Tablet, LY2484595, LY2484595 Reference Formulation (RF)
Evacetrapib · 5 trials · 4 indications
Percent change from baseline = 100\*(post-baseline assessment - baseline assessment)/baseline assessment. Higher values in the percent change from baseline represented an improvement for HDL-C and lower values in the percent change from baseline represented an improvement for LDL-C. Least Squares (LS) mean was adjusted for baseline value of the variable analyzed.
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
Least Squares (LS) Mean values were controlled for region, baseline measurement, treatment, visit, and treatment by visit interaction.
tlast is defined as the last time point with a measurable concentration of Evacetrapib.
| Arm | Type | Description |
|---|---|---|
| 30 milligrams (mg) LY2484595 | EXPERIMENTAL | Administered orally once daily for 12 weeks |
| 100 mg LY2484595 | EXPERIMENTAL | Administered orally once daily for 12 weeks |
| 500 mg LY2484595 | EXPERIMENTAL | Administered orally once daily for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Administered orally once daily for 12 weeks |
| 10 mg Atorvastatin | ACTIVE_COMPARATOR | Administered orally once daily for 12 weeks |
| 100 mg LY2484595 + 10 mg Atorvastatin | EXPERIMENTAL | Administered orally once daily for 12 weeks |
| 30 milligram (mg) LY2484595 monotherapy | EXPERIMENTAL | - |
| 100 mg LY2484595 monotherapy | EXPERIMENTAL | - |
| 500 mg LY2484595 monotherapy | EXPERIMENTAL | - |
| 20 mg Atorvastatin monotherapy | ACTIVE_COMPARATOR | - |
| 100 mg LY2484595 + 20 mg Atorvastatin | EXPERIMENTAL | - |
| 40 mg Simvastatin monotherapy | ACTIVE_COMPARATOR | - |
| 100 mg LY2484595 + 40 mg Simvastatin | EXPERIMENTAL | - |
| 10 mg Rosuvastatin monotherapy | ACTIVE_COMPARATOR | - |
| 100 mg LY2484595 + 10 mg Rosuvastatin | EXPERIMENTAL | - |
| Evacetrapib: Single Dose | EXPERIMENTAL | Single oral dose of evacetrapib on Day 1 |
| Evacetrapib: Multiple Dose 12 Weeks | EXPERIMENTAL | Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks |
| Evacetrapib: Multiple Dose 24 Weeks | EXPERIMENTAL | Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks |
| Evacetrapib: Multiple Dose 52 Weeks | EXPERIMENTAL | Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks |
| Evacetrapib (Participants With Renal Impairment) | EXPERIMENTAL | Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment. |
| Evacetrapib (Healthy Participants) | EXPERIMENTAL | Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function. |
| Evacetrapib (Healthy) | EXPERIMENTAL | Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function |
| Evacetrapib (Hepatic, Mild) | EXPERIMENTAL | Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment |
| Evacetrapib (Hepatic, Moderate) | EXPERIMENTAL | Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment |
| Evacetrapib (Hepatic, Severe) | EXPERIMENTAL | Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment |
| Name | Type | Description |
|---|---|---|
| LY2484595 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
| Atorvastatin | DRUG | Administered orally |
| Simvastatin | DRUG | Administered daily by mouth for 12 weeks |
| Rosuvastatin | DRUG | Administered daily by mouth for 12 weeks |
| Placebo for LY2484595 | DRUG | Administered daily by mouth for 12 weeks |
| Placebo for Statins | DRUG | Administered daily by mouth for 12 weeks |
| Evacetrapib | DRUG | Administered orally |
Inclusion Criteria: Have Low HDL-C or High LDL-C criteria as follows: Low HDL lipid criteria: * HDL-C \<45 milligrams per deciliter (mg/dL) (men) and \<50 mg/dL (women), and * LDL-C according to Japan Atherosclerosis Society (JAS) guidelines as follows: * LDL-C \<190 mg/dL (0-1 risk factors) ...
Top 4 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Lepodisiran |
| Illumina, Inc. | ILMN | 1 | PHASE1 | 18F-mFBG for administration |
Evacetrapib is an investigational small molecule developed by Eli Lilly and Company for cardiovascular disease and dyslipidemia. It is also known as Evacetrapib Tablet. It was studied in Phase 1 clinical trials, including a study in participants with abnormal cholesterol, and has not been approved for any indication.
Evacetrapib was studied for cardiovascular disease, dyslipidemia, and hepatic insufficiency. Clinical trials enrolled participants with abnormal cholesterol, liver impairment, and severe renal impairment. It remains an investigational agent and is not approved for these or any other uses.
Evacetrapib targets CETP, cholesteryl ester transfer protein, and acts as a CETP inhibitor. By inhibiting CETP, the drug was designed to affect cholesterol transport and lipid levels, which is why it was studied in dyslipidemia and cardiovascular disease.
Evacetrapib is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. The compound is also referenced by the code LY2484595 in Lilly's clinical study titles.
Evacetrapib is in Phase 1 clinical development. All three listed studies are Phase 1 and completed, and no active trials are ongoing. The drug is investigational and has not been approved by the FDA for any indication.
Evacetrapib has been studied in completed Phase 1 trials: NCT02168803 in participants with abnormal cholesterol, NCT01836185 in participants with hepatic impairment, and NCT01825889 in participants with severe renal impairment and healthy participants. All were conducted in the United States.
Yes, Evacetrapib Tablet is an alternative name for Evacetrapib, the CETP inhibitor developed by Eli Lilly and Company. Both names refer to the same investigational small molecule studied in Phase 1 trials for dyslipidemia, cardiovascular disease, and hepatic insufficiency.